AI Article Synopsis
- The use of monoclonal antibodies targeting tumor necrosis factor-α has significantly improved treatment outcomes for inflammatory bowel disease (IBD), enhancing patient quality of life and reducing hospital visits and steroid use.
- However, these biologics are expensive, leading to high medical costs for IBD patients.
- To address affordability, biosimilars—similar but not identical therapeutic antibodies—have been introduced, but their acceptance varies across regions, prompting a discussion of their benefits, barriers to use, and safety in clinical studies.
Article Abstract
The introduction of therapeutic monoclonal antibodies directed against tumor necrosis factor-α has revolutionized the treatment of inflammatory bowel disease (IBD) by improving quality of life, decreasing the frequency and length of hospital admissions, and reducing corticosteroid use. Nevertheless, biologics are very expensive, substantially contributing to the cost of care for patients with IBD. To reduce this cost and improve treatment access, biosimilars, which are therapeutic monoclonal antibodies (biologicals) similar to but not identical to the reference biologic, were introduced. Despite their potential benefits, the adoption and uptake of biosimilars have varied considerably across the USA and Europe. Here, we highlight the current biosimilar therapeutic landscape, discuss barriers to their use, and provide an overview of published studies evaluating the efficacy and safety of biosimilars in IBD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-021-07114-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence of Venous Thromboembolism in Asian Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
J Gastroenterol Hepatol
January 2025
Division of Gastroenterology, Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Republic of Korea.
Background/aims: Although incidence and prevalence of inflammatory bowel disease (IBD) have been gradually increasing throughout Asia, incidence of venous thromboembolism (VTE) in Asia is relatively lower than that in Western and is not well known. This study aimed to evaluate incidence of VTE in Asian IBD patients using a systematic review and meta-analysis.
Methods: Studies were identified through literature search of the PubMed, Embase, and Cochrane databases (from inception inclusive April 2024) for English studies.
MC-LR induces and exacerbates Colitis in mice through the JAK1/STAT3 pathway.
J Toxicol Environ Health A
January 2025
Hunan Province Key Laboratory of Typical Environmental Pollution and Health Hazards, School of Public Health, University of South China, Hengyang, China.
Inflammatory bowel disease (IBD) is a complex gastrointestinal disorder attributed to genetic and environmental factors. Microcystin-leucine-arginine (MC-LR) is an environmental toxin that accumulates in the gut and produces intestinal damage. The aim of this study was to investigate the effects of exposure to MC-LR on development and progression of IBD as well examine the underlying mechanisms of microcystin-initiated tissue damage.
View Article and Find Full Text PDFNutraceutical Impact of Pumpkin Seed Oil on Expression Levels of EZH-2 and KRT-14 Genes against DSS-induced Inflammatory Bowel Disease in the Rat Model.
Cell Biochem Biophys
January 2025
Department of Food Science, Faculty of Agriculture, Zagazig University, Zagazig, 44519, Egypt.
Inflammatory bowel disease is a collection of intestinal disorders that cause inflammation in the digestive tract. Prolonged inflammation in the gastrointestinal tract is a major risk factor for colorectal cancer. The objective of this study was to fucus on gene expression levels of (KRT-14; associated with epithelial cell integrity) and enhancer of zeste homolog-1 (EZH-2; involved in cellular proliferation) in a IBD rat model in order to rule out impact of nutraceuticals (pumpkin seed oil; PSO) as a complementary approach to conventional treatments of IBD.
View Article and Find Full Text PDFMucus-penetrating microbiota drive chronic low-grade intestinal inflammation and metabolic dysregulation.
Gut Microbes
December 2025
Microbiome-Host Interactions, Institut Pasteur, Université Paris Cité, INSERM U1306, CNRS UMR6047, Paris, France.
Metabolic syndrome is, in humans, associated with alterations in the composition and localization of the intestinal microbiota, including encroachment of bacteria within the colon's inner mucus layer. Possible promoters of these events include dietary emulsifiers, such as carboxymethylcellulose (CMC) and polysorbate-80 (P80), which, in mice, result in altered microbiota composition, encroachment, low-grade inflammation and metabolic syndrome. While assessments of gut microbiota composition have largely focused on fecal/luminal samples, we hypothesize an outsized role for changes in mucus microbiota in driving low-grade inflammation and its consequences.
View Article and Find Full Text PDFMoxifloxacin plus Cordyceps polysaccharide ameliorate intestinal barrier damage due to abdominal infection via anti-inflammation and immune regulation under simulated microgravity.
Life Sci Space Res (Amst)
February 2025
Department of General Surgery, the 306th Hospital of PLA-Peking University Teaching Hospital, Beijing 100101, PR China; Department of General Surgery, the Ninth Medical Center of PLA General Hospital, Beijing 100101, PR China. Electronic address:
Background: Currently, there is limited research on the impact of abdominal infection on intestinal damage under microgravity conditions. Cordyceps polysaccharide (CPS), the main active ingredient of Cordyceps, has demonstrated various pharmacological effects, including anti-inflammatory, antioxidant, and immunomodulatory properties. Moxifloxacin (MXF) is a fourth-generation quinolone antibiotic that is believed to have a dual regulatory effect on immune system activation and suppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!